Skip to main content
ZheJiang Tailin Bioengineering Co.,Ltd logo

ZheJiang Tailin Bioengineering Co.,Ltd — Investor Relations & Filings

Ticker · 300813 ISIN · CNE100003S89 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,000 across all filing types
Latest filing 2024-01-02 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300813

About ZheJiang Tailin Bioengineering Co.,Ltd

https://www.tailingood.com

ZheJiang Tailin Bioengineering Co.,Ltd. specializes in the research, development, and manufacturing of high-tech equipment for life sciences and pharmaceutical engineering. The company provides integrated solutions for microbial control, sterility testing, and aseptic processing. Its core product portfolio includes sterility test canisters and pumps, microbial limit testing systems, and hydrogen peroxide vapor (VHP) decontamination units. Tailin also develops advanced isolator technology for containment and aseptic applications, alongside analytical instruments such as Total Organic Carbon (TOC) analyzers and filter integrity testers. These products are designed to meet international regulatory standards, including GMP, USP, and EP. The company serves sectors such as biopharmaceuticals, medical devices, and laboratory research, focusing on product safety and quality through specialized engineering and microbial detection technologies.

Recent filings

Filing Released Lang Actions
关于2023年第四季度可转换公司债券转股情况公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the convertible bonds (convertible company bonds) of Zhejiang Tailin Biotechnology Co., Ltd. It details the bond issuance, listing, conversion period, conversion price adjustments, and the bond conversion activity for the fourth quarter of 2023. It also includes changes in the company's total shares due to bond conversions. The document is structured as a formal announcement with specific bond codes, dates, and regulatory references to the Shenzhen Stock Exchange and China Securities Regulatory Commission. The content focuses on convertible bond conversion updates and share capital changes rather than financial statements or earnings. The document length is 3038 characters, which is relatively short and typical for an announcement rather than a full report. It does not contain comprehensive financial data or management discussion but provides detailed information on bond conversion and share capital changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP), as it relates to financing activities and capital structure changes due to convertible bond conversions.
2024-01-02 Chinese
关于全资子公司参股江苏宏众百德生物科技有限公司的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Zhejiang Tailin Biotechnology Co., Ltd. regarding an investment by its wholly-owned subsidiary in another company, Jiangsu Hongzhong Baide Biotechnology Co., Ltd. It details the investment amount, shareholding structure changes, approval procedures, contract terms, risks, and impact on the company. There are no financial statements or comprehensive financial performance data presented. The document is a formal disclosure of a capital investment transaction, which fits the category of Capital/Financing Update (CAP). It is not an annual or interim report, audit report, or earnings release. It is not a regulatory filing or report publication announcement since it contains substantive transaction details rather than just a notice or certification. Therefore, the correct classification is CAP with high confidence.
2024-01-02 Chinese
关于泰林转债恢复转股的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement regarding the resumption of convertible bond conversion rights for the company's convertible bonds ("泰林转债"). It includes details about bond codes, suspension and resumption dates for conversion, regulatory approvals, and references to related shareholder meetings and announcements. The document does not contain financial statements or detailed financial analysis but is a regulatory disclosure about bond conversion status and related shareholder decisions. It is not an annual report, earnings release, or detailed financial report. Given its nature as a formal announcement about convertible bond status and related regulatory compliance, it fits best under Capital/Financing Update (CAP). The document length is short (1235 characters), and it is not merely announcing the publication of a report but providing substantive update on convertible bond status.
2023-12-25 Chinese
关于全资子公司竞拍取得资产的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of an asset acquisition by a wholly-owned subsidiary of Zhejiang Tailin Biotechnology Co., Ltd. It details the transaction overview, contract terms, payment, delivery, and risk warnings. The document is relatively short (2587 characters) and focuses on the update of a specific transaction rather than presenting financial statements or comprehensive financial data. There is no indication of it being a full financial report, audit report, or regulatory certification. It is not a call transcript, earnings release, or management report. The content fits best as a Capital/Financing Update (CAP) because it informs about a financing-related transaction (asset acquisition) progress and contract details. Therefore, the appropriate classification is CAP with high confidence.
2023-12-25 Chinese
关于泰林转债回售的第三次提示性公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the third reminder for the repurchase (回售) of convertible bonds (泰林转债) issued by Zhejiang Tailin Biotechnology Co., Ltd. It includes specific dates for the repurchase application period, payment dates, repurchase price calculations, rights of bondholders, procedural details, and legal opinions related to the repurchase. The document is regulatory in nature, providing information about a financing instrument (convertible bonds) and the company's obligations and procedures related to bond repurchase. It is not a financial report, earnings release, or management discussion. It is also not a simple announcement of a report publication but a substantive update on capital/financing activity. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is 3286 characters, which is sufficient for a detailed announcement but not a full financial report. Confidence is high given the detailed financial and procedural content related to bond repurchase.
2023-12-25 Chinese
关于持股5%以上股东减持计划期限届满暨减持计划实施结果的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the completion of a shareholding reduction plan by a shareholder holding more than 5% of the company's shares. It details the number of shares reduced, the methods used, and compliance with relevant regulations. The content focuses on shareholding changes by a major shareholder and the results of their reduction plan. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels. The document is not a full financial report, earnings release, or management report, nor is it a regulatory filing or announcement of a report publication. Therefore, the appropriate classification is MRQ.
2023-12-22 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.